Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Topline symbols : BHC save search
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
Published: 2021-09-30 (Crawled : 12:00) - biospace.com/
BHC | $8.63 -1.48% -1.04% 3M
|
Health Technology
|
| O: -0.39%
H: 0.61%
C: -0.64%
dry eye disease eye eye disease results topline phase 3 trial
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
Published: 2021-04-22 (Crawled : 12:00) - biospace.com/
BHC | $8.63 -1.48% -1.04% 3M
|
Health Technology
|
| O: 0.1%
H: 0.64%
C: -0.37%
acne results topline phase 3 trial
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
Published: 2021-04-13 (Crawled : 13:00) - biospace.com/
BHC | $8.63 -1.48% -1.04% 3M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -0.5%
dry eye disease eye eye disease results topline phase 3 trial
Gainers vs Losers
| 28% | 72% |
Top 10 Gainers
AMPL | $9.83 2.08% 2.7K
|
CL | $86.445 0.32% 43K
|
Consumer Non-Durables
AESI | $22.105 0.11% 4.7K
|
n/a
AJG | $232.2 0.05% 11K
|
Finance
EXPE 4 | $128.72 0.05% 18K
|
Consumer Services
BCAB | $2.86 3.6K
|
DTE | $105.365 -0.15% 5.1K
|
Utilities
AME | $178.705 -0.19% 9.1K
|
Producer Manufacturing
ESTC 4 | $94.65 -0.21% 9.2K
|
Technology Services
EXC 4 | $36.19 -0.22% 48K
|
Utilities
Your saved searches
Save your searches and get alerts when important news are released.